$378.02
-3.98 (-1.04%)
USD · as of 2026-08-19 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where HUM is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
1 interventional
Held by 22 tracked-famous managers (Dodge & Cox, EAGLE CAPITAL MANAGEMENT LLC, MARSHALL WACE, LLP, CITADEL ADVISORS LLC, Holocene Advisors, LP, +17 more) · FINRA short interest 2.2 days to cover (settled 2026-07-31) · government filings 180d: 0 congress / 2 executive
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| Educational Intervention to Increase Select Guideline-recommended Cardioprotective Medications in Patients With DiabetesNCT04862858Percentage of individuals who initiate guideline-based SGLT2i or GLP-1 RA medications with cardiovascular benefit, excluding combination products, based on administrative claims dataRandomized · Open-label · Health services researchStudy Protocol and Statistical Analysis Plan ↗ | Not applicable | Unknown status | Other: Educational Intervention | Diabetes Mellitus, Type 2, Cardiovascular Diseases | 4,197 | 2021-11-30actual | 2022-05-20 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19